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esponsibility of InstAbstract Ginsenoside compound K (GCK), the main metabolite of protopanaxadiol constituents of
Panax ginseng, easily produces alkali metal adduct ions during mass spectrometry particularly with
lithium. Accordingly, we have developed a rapid and sensitive liquid chromatography–tandem mass
spectrometric method for analysis of GCK in human plasma based on formation of a lithium adduct. The
analyte and paclitaxel (internal standard) were extracted from 50 mL human plasma using methyl tert-
butyl ether. Chromatographic separation was performed on a Phenomenex Gemini C18 column
(50 mm 2.0 mm; 5 μm) using stepwise gradient elution with acetonitrile–water and 0.2 mmol/L lithium
carbonate at a ﬂow rate of 0.5 mL/min. Detection was performed in the positive ion mode using multiple
reaction monitoring of the transitions at m/z 629-449 for the GCK-lithium adduct and m/z 860-292 for
the adduct of paclitaxel. The assay was linear in the concentration range 1.00–1000 ng/mL (r240.9988)
with intra- and inter-day precision of 78.4% and accuracy in the range of 4.8% to 6.5%. Recovery,
stability and matrix effects were all satisfactory. The method was successfully applied to a pharmaco-
kinetic study involving administration of a single GCK 50 mg tablet to healthy Chinese volunteers.
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Ginseng is a traditional Chinese medicine widely used in Asian
countries. Ginsenoside compound K (GCK; 20-O-β-(D-glucopyr-
anosyl)-20(S)-protopanaxadiol; Fig. 1) is a metabolite of proto-
panaxadiol ginsenosides, such as Rb1, Rb2, and Rc
1–3 produced by
human intestinal bacteria after oral ingestion. Previous studies
have shown that GCK exerts stronger anti-colorectal cancer
activity than Rb1
4 and exhibits antiapoptotic5, antidiabetic6,
antiallergic7, anti-inﬂammatory8, and antiaging activities9. Despite
these promising beneﬁcial effects, drug development of GCK is
compromised by the lack of a rapid and reliable method for its
quantitation in in vivo and in vitro studies.
Several bioanalytical methods have been developed for GCK,
but they were usually aimed at simultaneous determination of
ginsenosides which are both time-consuming and relatively
insensitive. The methods include high-performance liquid chro-
matography with ultraviolet detection (HPLC–UV)10, ultra-
performance liquid chromatography coupled to time-of-ﬂight mass
spectrometry (UPLC/TOF–MS)11, and liquid chromatography–
tandem mass spectrometry (LC–MS/MS)12. One LC–MS/MS
method13 using the negative ion mode has been reported for
determination of GCK in human plasma, but in our hands, the
response of the [MH] ion was negligible.
As a neutral compound, GCK is not easily ionized during MS
and gives only a weak response in both positive and negative ion
modes. A possible method to improve the MS response in the
positive ion mode is to add alkali metal salts or alkyl ammonium
salts14–17. This was the case for the determination of decitabine in
human plasma by hydrophilic interaction liquid chromatography–
tandem mass spectrometry (HILIC–MS/MS)18 and for paclitaxel
and hydroxylated metabolites in rat plasma by LC–MS/MS19, both
assays using lithium adduct detection. In the present study, we
have used this technology to determine GCK in human plasma
using paclitaxel as internal standard (IS) and applied the method to
a pharmacokinetic study of GCK in healthy Chinese volunteers.2. Experimental
2.1. Chemicals and additives
Materials and their suppliers were as follows: GCK (chemical
purity 98.9%), Zhejiang Hisun Pharmaceutical Co., Ltd. (Zhejiang,
China); paclitaxel (chemical purity 98.0%), Jiangsu Hengrui
Medicine Co., Ltd. (Jiangsu, China); methyl tertiary butyl ether
(chemical purity 99.0%), Sinopharm Chemical Reagent Co., Ltd.
(Shanghai, China); lithium carbonate (chemical purity 99%),Figure 1 Structure of GCK.Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China);
HPLC-grade methanol and acetonitrile, Sigma–Aldrich (St. Louis,
USA). Human blank plasma was provided by Shuguang Hospital
(Shanghai, China) and deionized water puriﬁed using a Millipore
Milli-Q Gradient Water Puriﬁcation System (Molsheim, France).
2.2. Instrumentation
The HPLC system consisting of two LC-30AD pumps and an SIL-
30AC autosampler (Shimadzu, Kyoto, Japan) was coupled to an
AB Sciex Qtrap 5500 System (Applied Biosystems, Foster City,
USA) equipped with a TurboIonSpray ionization interface. Ana-
lyst Version 1.5.2 (Applied Biosystems) was used for data
acquisition. Centrifugation employed a CT 15 RE high-speed
desktop centrifuge (Hitachi, Tokyo, Japan).
2.3. LC–MS/MS conditions
Lithium adducts of GCK and IS were separated from matrix
components on a Phenomenex Gemini C18 column
(50 mm 2.0 mm, 5 μm) using stepwise gradient elution with
0.2 mmol/L lithium carbonate in water (solvent A) and aceto-
nitrile (solvent B) at a ﬂow rate of 0.5 mL/min. The gradient
program was 0–0.5 min 50% B; 0.5–1.8 min 80% B; 1.8 min
50% B. The autosampler was maintained at 4 1C and the
injection volume was 5 μL.
The electrospray ionization (ESI) source of the mass spectro-
meter was operated in the positive ion mode. Detection was
by multiple reaction monitoring (MRM) of the transitions at
m/z 629-449 for the lithium adduct ion of GCK and
m/z 860-292 for that of paclitaxel with a dwell time of
100 ms. Optimal MS parameters were as follows: curtain gas
35 psi; collision gas medium; nebulizer gas (GS1) and turbo gas
(GS2) 50 psi; ion spray voltage 5000 V; source temperature
400 1C; collision energies 44 and 35 eV for GCK and IS,
respectively; declustering potential 40 V for both GCK and IS.
2.4. Preparation of calibration standards and quality control
(QC) samples
Stock solutions of GCK (1 mg/mL) were prepared in methanol and
stored at 4 1C. Standard solutions were prepared by serial dilution
with 50% aqueous methanol to concentrations of 50.0, 150, 500,
1500, 5000, 15,000 and 50,000 ng/mL. Calibration standards for
GCK were prepared by spiking 980 μL blank human plasma with
20 μL of the respective standard solutions to give ﬁnal concentra-
tions of 1.00, 3.00, 10.0, 30.0, 100, 300 and 1000 ng/mL. All
solutions were stored at 80 1C until required. LLOQ (lower limit
of quantitation), low, medium and high QC samples were prepared
in a similar way at concentrations of 1.00, 2.00, 30.0, and 800 ng/
mL respectively and also stored at 80 1C. An IS stock solution
in methanol was diluted with 50% aqueous methanol to obtain a
200 ng/mL working IS solution before storage at 4 1C.
2.5. Sample preparation
200 μL water and 50 μL IS working solution were added to an
aliquot of plasma. After vortex-mixing, the sample was extracted
by shaking with 500 mL methyl tert-butyl ether for 5 min and
subsequently centrifuged at 14,000 g for 5 min at room tem-
perature (20 1C). The organic phase was transferred to another
Validation of GCK by LC–MS/MS 463tube and evaporated to dryness at 40 1C under a stream of nitrogen
in a TurboVap evaporator (Zymark, Hopkinton, USA). The
residue was reconstituted in 200 μL 50% aqueous methanol and
injected into the LCMS/MS system.
2.6. Assay validation
This was carried out in accordance with EMA guidelines20.
2.6.1. Selectivity
Selectivity was evaluated by analyzing three replicates of six
batches of human non-hemolyzed plasma and one batch of human
hemolyzed plasma (prepared by adding 2% lysed whole blood to
plasma) at the LLOQ level. The assay was considered free of
interference at the retention time of GCK and IS if the response
was o20% of that of the LLOQ for GCK and o5% of that of
the IS.
2.6.2. Linearity
This was evaluated by least squares analysis of calibration curves
based on peak area ratios of analyte to IS (y) weighted using 1/x2
(x, concentration). Linearity was accepted when the correlation
coefﬁcient (r2) was 40.99 and back-calculated concentrations
were 715% of nominal values (720% at the LLOQ).
2.6.3. Precision and accuracy
Intra- and inter-day precision and accuracy were determined by
analyzing six replicate QC samples on three successive days.
Concentrations were determined using duplicate calibration curves
prepared independently. Precision as relative standard deviation
(RSD) and accuracy as relative error (RE) were considered
acceptable if values were o15% and 715% (720% at the
LLOQ), respectively.
2.6.4. Recovery and matrix effects
Recovery of analyte and IS was determined by comparing peak
areas of extracted low, medium and high QC samples with those of
extracted blank plasma spiked with solutions at corresponding
concentrations. Matrix effects were evaluated by comparing peak
areas of spiked extracts of six samples of blank non-hemolyzed
plasma and one sample of hemolyzed plasma with those of three
replicates of water spiked with GCK at corresponding concentra-
tions and IS. Precision for assay of the seven samples should be
o15%.
2.6.5. Stability
Stability of GCK in human plasma was evaluated by assay in
triplicate of plasma samples at low and high concentrations (2.00
and 800 ng/mL) stored under the following conditions: 80 1C
for 32 days; after three freeze–thaw cycles from 80 1C; room
temperature for 6 h. The stability of processed samples in the
autosampler at 4 1C for 24 h was also evaluated. Finally, stability
of the GCK stock solution at room temperature for 6 h and that of
the GCK stock solution and IS working solution in a refrigerator at
473 1C for 32 days were tested. Stability in plasma and solutions
was considered acceptable if concentrations were o15% and
r10%, respectively, of initial levels.
2.6.6. Carry-over
Carry-over was assessed by assay of a double blank sample (no
GCK, no IS) immediately after assay of the highest calibrationstandard (1000 ng/mL). It was considered acceptable for GCK if
the response waso20% of the LLOQ standard and for IS ifo5%
of the control zero sample.
2.7. Pharmacokinetic study
The method was applied to a pharmacokinetic study involving oral
administration of a GCK 50 mg tablet (Hisun Pharmaceutical Co.,
Ltd., Zhejiang, China) with 200 mL water to 12 healthy Chinese
volunteers (six males, six females, aged 25–32 years). The study
was approved by the Ethics Committee of the Third Xiangya
Hospital, Central South University (Changsha, China). Blood
samples (4 mL) were collected into sodium heparin-containing
tubes predose and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12
and 24 h postdose. Plasma was collected after centrifugation at
2000 g for 10 min and stored at 80 1C until analysis.3. Results and discussion
3.1. Mass spectrometric conditions
In the early stages of method development, ionization of GCK was
investigated in both negative and positive ion modes. Because
GCK is a neutral compound with low polarity, its MS response in
ESI was weak under both conditions. However, in the negative ion
mode, the responses of the solvent adduct ions [MþHCOO]
(m/z 667) and [MþCH3COO] (m/z 681), produced in the
presence of formic acid and acetic acid, respectively, were much
stronger than that of [MH] (m/z 621). Unfortunately the
[MþHCOO] ion was unstable and gave highly variable response
between two calibration curve determinations.
In the positive ion mode, [MþH]þ was not detected and the
most abundant ions produced from GCK were [MþNa]þ followed
by [M–Glu–2H2OþH]þ. The response of the [M–Glu–2H2OþH]þ
ion at 1 ng/mL GCK was too weak for quantitation, and after
adjusting either the temperature or ejection voltage source, the
fragment ions of [MþNa]þ were unstable. In the presence of
lithium ions, both lithium and sodium adducts were observed but
only the [MþLi]þ ion fragmented easily to produce stable product
ions with substantial intensity. Therefore, the positive ion mode
was selected to quantitate GCK and IS using their most stable
fragment ions at m/z 449 and 292 respectively in the MRM mode.
The product ion spectra of GCK and IS are presented in Fig. 2.
3.2. Chromatographic conditions
Several C18 HPLC columns were evaluated including the ASB
and Agilent XDB columns but, in all cases, the IS gave poor
retention even at low acetonitrile or methanol levels in the mobile
phase. However, the Phenomenex Gemini C18 column
(50 mm 2.0 mm, 5 μm) gave adequate retention, selectivity and
peak shape.
The MS responses of analyte (m/z 425) and IS remained intense
when methanol or acetonitrile was used as the organic modiﬁer.
However, acetonitrile gave shorter retention time. Initially 5 mmol/L
ammonium acetate was evaluated as solvent A, but the response of the
analyte was three-fold lower than using water. Similarly, the inclusion
of either formic acid or acetic acid produced a two-fold reduction in
analyte response. The previously reported assay of 20(S)-protopanax-
adiol in rat plasma17 employed 25 mmol/L lithium acetate, but for
Figure 2 Product ion spectra of [MþLi]þ of (A) GCK and (B)
paclitaxel as well as proposed fragmentation patterns.
Figure 3 Representative MRM chromatograms of (I) GCK and (II) paclitaxe
plasma sample spiked with GCK (1.0 ng/mL) and paclitaxel (200 ng/mL) and
50 mg tablet.
Yunhui Chen et al.464GCK only 0.2 mmol/L lithium carbonate was needed to generate a
stable [MþLi]þ signal, presumably because the water content of the
mobile phase was relatively low. A column temperature of 40 1C and
a ﬂow rate of 0.5 mL/min also contributed to producing symmetrical
peaks for GCK and paclitaxel with retention time of only 1.5 and
1.3 min, respectively.
3.3. Sample preparation
Sample preparation by protein precipitation was initially evaluated,
but strong matrix effects ruled it out. Liquid–liquid extraction
(LLE) with various solvents (methyl tert-butyl ether, ethyl acetate,
n-hexane, n-hexane/dichloromethane/isopropanol 2:1:0.1, v/v/v)




Fig. 3 presents typical chromatograms of blank plasma, plasma
spiked with IS, plasma spiked with GCK at the LLOQ and IS, and
a plasma sample collected 1.5 h after oral administration of a GCKl in (A) blank plasma, (B) plasma spiked with paclitaxel (200 ng/mL), (C)
(D) a plasma sample collected 1.5 h after oral administration of a GCK
Table 1 Precision and accuracy data for analysis of GCK in human plasma.
Nominal conc. (ng/mL) Mean7SD (ng/mL) Inter-day RSD (%) Intra-day RSD (%) Accuracy as RE (%)
1.00 0.9970.05 8.4 4.7 1.35
2.00 1.9370.08 3.6 4.2 3.36
30.0 29.071.0 4.3 3.2 2.78
800 835727 6.0 2.6 4.32
Data are based on the assay of six replicates per day on three separate days.
Table 2 Recovery and matrix effects for GCK and paclitaxel (IS).
Compd. Nominal conc. (ng/mL) Recovery Matrix effects
Mean7SD (%) RSD (%) Mean7SD (%) RSD (%)
GCK 2.00 80.072.4 3.8 10974 3.5
30.0 81.973.9 3.8
800 83.470.9 1.1 11173 2.7
IS 200 81.973.9 1.6
Data are based on the assay of six samples of blank non-hemolyzed plasma and one sample of hemolyzed plasma.
Table 3 Stability of GCK in human plasma and processed
samples under various storage conditions (n¼3).
Storage condition Concentration (ng/mL) RSD (%)
Nominal Mean7SD






Room temperature/6 h 2.00 1.9370.20 3.3
800 781710 2.4




Figure 4 Mean plasma concentration-time proﬁle of GCK after
single oral administration of a 50 mg tablet to healthy volunteers (data
are mean7SD, n¼12).
Validation of GCK by LC–MS/MS 46550 mg tablet. The S/N ratio at the LLOQ was 410.3 and analyte
and IS were free of interference from endogenous substances in
both non-hemolyzed and hemolyzed plasma.
3.4.2. Linearity and LLOQ
The assay was shown to be linear in the range 1.00–1000 ng/mL
with a typical linear regression equation of y¼0.00631xþ0.00112
(r¼0.9989). The LLOQ of GCK was 1.00 ng/mL.
3.4.3. Precision and accuracy
Intra- and inter-day precision and accuracy data at QC concentra-
tions are summarized in Table 1. The results demonstrate that
accuracy and precision are within acceptable ranges.
3.4.4. Recovery and matrix effects
Recovery of GCK from low, medium and high QC samples and of
the IS are shown in Table 2. In all cases recovery was Z80.0%.Evaluation of matrix effects indicate concentrations were 109%
and 111% of nominal low and high concentrations and were not
signiﬁcant issue.
3.4.5. Stability
The results of the stability tests of GCK in plasma and processed
samples are shown in Table 3. GCK was shown to be stable under
all storage conditions tested. The stock solution of GCK and
working solution of IS were also found to be stable under the
conditions tested.
3.4.6. Carry-over
No signiﬁcant carry-over was observed for the analyte and IS
when analyzing blank plasma immediately after the highest
calibration standard (1000 ng/mL).
3.5. Pharmacokinetic study
The assay was successfully applied to a pharmacokinetic study in
12 healthy Chinese volunteers after oral administration of a GCK
Yunhui Chen et al.46650 mg tablet. The mean plasma concentration–time proﬁle of GCK
is shown in Fig. 4. Non-compartmental pharmacokinetic parameters
calculated using WinNonlin 6.1 were as follows: Cmax,
6527180 ng/mL; Tmax, 2.6371.17 h; t1/2, 5.9770.68 h; AUC(0–t),
36507850 ng  h/mL; AUC(0–1), 38107890 ng  h/mL.
3.6. Comparison with previous methods
The only previously reported LC–MS/MS assay for GCK in
human plasma used the negative ion mode and digoxin as IS13.
The present method has the following advantages: (1) The
sensitivity is substantially better due to the MRM of [MþLi]þ
ions instead of [MH]; (2) the LLOQ of 1 ng/mL is achieved
using 50 μL plasma instead of 100 μL; and (3) the method is more
accurate, precise and reproducible than the previous method,
probably because the difference in polarity between GCK and
paclitaxel is smaller than between GCK and digoxin and because
the IS was added before but not after LLE.4. Conclusions
An LC–MS/MS method for determination of GCK in human
plasma based on formation of lithium adducts of the analyte and IS
(paclitaxel) has been developed and validated. The assay is rapid
and sensitive and has the potential to allow relatively high sample
throughput and to be useful in the assay of other neutral
compounds. The method was successfully applied to a pharmaco-
kinetic study involving a single oral administration of GCK to
healthy Chinese volunteers.
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